Nilforushan Naveed, Abolfathzadeh Navid, Najafzadeh Farhad, Samimifar Deniz
Eye Research Center, The Five Senses Institute, Rassoul Akram Hospital, 440827Iran University of Medical Sciences, Tehran, Iran.
Eur J Ophthalmol. 2023 Jan;33(1):319-323. doi: 10.1177/11206721221108253. Epub 2022 Jun 13.
To report the effect of subtenon triamcinolone acetonide (TA) injection in the treatment of serous choroidal detachment (SCD) after glaucoma surgery.
In this prospective case series, patients with persistent, non-resolving, or progressive SCD after glaucoma surgery were enrolled. For those with non-resolving or progressive SCD despite of using systemic corticosteroids, topical atropine and topical steroids, one milliliter of TA (40mg/mL) was injected inferotemporally into the posterior subtenon space.
Sixteen consecutive patients with a mean ± SD age of 70.12 ± 11.12 years were included in this study. After injection of subtenon TA, SCD was completely resolved after 1 to 4 weeks, with deepening of the anterior chamber in all cases. All cases were followed for at least 6 months after the injection with no signs of recurrence.
Subtenon injection of TA is a safe and effective modality of treatment for resolving a persistent or progressive SCD after glaucoma surgeries.
报告球后注射曲安奈德（TA）治疗青光眼术后浆液性脉络膜脱离（SCD）的效果。
在这个前瞻性病例系列研究中，纳入青光眼术后出现持续性、未消退或进行性SCD的患者。对于那些尽管使用了全身皮质类固醇、局部阿托品和局部类固醇但SCD仍未消退或进展的患者，将1毫升TA（40mg/mL）颞下注射到球后间隙。
本研究纳入了16例患者，平均年龄为70.12±11.12岁（均值±标准差）。球后注射TA后，SCD在1至4周内完全消退，所有病例前房均加深。所有病例在注射后至少随访6个月，无复发迹象。
球后注射TA是治疗青光眼术后持续性或进行性SCD的一种安全有效的方法。
